Results 231 to 240 of about 816,685 (307)

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

From rough to refined: Applying diamond standards to CAR Treg development. [PDF]

Mol Ther Methods Clin Dev
Hamilton FW, Ferreira LMR.
europepmc   +1 more source

Imperial strategy of cancer cells through mitochondrial transfer

Molecular Oncology, EarlyView.
Cangkrama et al. demonstrated that cancer cells donate their mitochondria to fibroblasts through mitochondrial transfer, reprogramming them into ‘MitoCAF’. Likewise, our group has identified mitochondrial transfer from cancer cells to tumor infiltrating lymphocytes, resulting in mitochondrial ‘hijack’ and impaired antitumor immunity.
Takamasa Ishino, Yosuke Togashi
wiley   +1 more source

Preptin, PPARγ, and NLRP3 as inflammatory biomarkers in pediatric obesity - a pilot study. [PDF]

BMC Pediatr
Kahraman EK, Donma O, Donma MM, Yılmaz A, Güzel S.   +4 more
europepmc   +1 more source

INFLUENCE OF THE DURATION OF IL-2 RECEPTOR (IL-2R) BLOCKADE ON THE INCIDENCE OF ACUTE REJECTION EPISODES IN RENAL TRANSPLANTATION

, 1998
John M. Kovarik, Christophe Gerbeau, Michael Hall, Arne Schmidt   +3 more
openalex   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Concomitant immunity against superimposed homologous Echinostoma caproni infections in mice is mediated by interleuquin-25. [PDF]

Mem Inst Oswaldo Cruz
Cociancic P, Fiallos E, Esteban JG, Muñoz-Antoli C, Toledo R.   +4 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment. [PDF]

Front Immunol
Rane R, Li F, Williams A, Jayadev A, Tran NL, Winkles JA, Kim GB.   +6 more
europepmc   +1 more source

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Molecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source